JP2025510678A5 - - Google Patents

Info

Publication number
JP2025510678A5
JP2025510678A5 JP2024555897A JP2024555897A JP2025510678A5 JP 2025510678 A5 JP2025510678 A5 JP 2025510678A5 JP 2024555897 A JP2024555897 A JP 2024555897A JP 2024555897 A JP2024555897 A JP 2024555897A JP 2025510678 A5 JP2025510678 A5 JP 2025510678A5
Authority
JP
Japan
Prior art keywords
antibody conjugate
conjugate according
pharmaceutically acceptable
antibody
fuc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024555897A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025510678A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2023/057565 external-priority patent/WO2023180489A1/en
Publication of JP2025510678A publication Critical patent/JP2025510678A/ja
Publication of JP2025510678A5 publication Critical patent/JP2025510678A5/ja
Pending legal-status Critical Current

Links

JP2024555897A 2022-03-23 2023-03-23 カルシノエンビロニック抗原を発現する腫瘍を標的化するための抗体コンジュゲート Pending JP2025510678A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22163928 2022-03-23
EP22163928.9 2022-03-23
PCT/EP2023/057565 WO2023180489A1 (en) 2022-03-23 2023-03-23 Antibody-conjugates for targeting of tumours expressing carcinoembyronic antigen

Publications (2)

Publication Number Publication Date
JP2025510678A JP2025510678A (ja) 2025-04-15
JP2025510678A5 true JP2025510678A5 (cg-RX-API-DMAC10.html) 2026-04-01

Family

ID=80930396

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024555897A Pending JP2025510678A (ja) 2022-03-23 2023-03-23 カルシノエンビロニック抗原を発現する腫瘍を標的化するための抗体コンジュゲート

Country Status (10)

Country Link
US (1) US20250082770A1 (cg-RX-API-DMAC10.html)
EP (1) EP4496595A1 (cg-RX-API-DMAC10.html)
JP (1) JP2025510678A (cg-RX-API-DMAC10.html)
KR (1) KR20250024741A (cg-RX-API-DMAC10.html)
CN (1) CN119233830A (cg-RX-API-DMAC10.html)
AU (1) AU2023237620A1 (cg-RX-API-DMAC10.html)
CA (1) CA3254964A1 (cg-RX-API-DMAC10.html)
IL (1) IL315205A (cg-RX-API-DMAC10.html)
MX (1) MX2024011519A (cg-RX-API-DMAC10.html)
WO (1) WO2023180489A1 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3876998A1 (en) 2018-11-05 2021-09-15 Synaffix B.V. Antibody-conjugates for targeting of tumours expressing trop-2
IL315366A (en) 2022-03-23 2024-11-01 Synaffix Bv Antibody pairs for targeting PTK7-expressing tumors
EP4737483A1 (en) * 2023-06-30 2026-05-06 Daiichi Sankyo Company, Limited Antibody-drug conjugate production method including purification step using activated carbon material
WO2025238253A1 (en) * 2024-05-16 2025-11-20 Synaffix B.V. Antibody-oligonucleotide conjugates
WO2026158363A1 (zh) * 2025-01-22 2026-07-30 石药集团巨石生物制药有限公司 抗体-药物偶联物及其用途

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4939255A (en) 1987-06-24 1990-07-03 Daiichi Pharmaceutical Co., Ltd. Hexa-cyclic camptothecin derivatives
US5872215A (en) 1991-12-02 1999-02-16 Medical Research Council Specific binding members, materials and methods
GB9317423D0 (en) 1993-08-21 1993-10-06 Imp Cancer Res Tech Monoclonal antibodies
GB9324807D0 (en) 1993-12-03 1994-01-19 Cancer Res Campaign Tech Tumour antibody
US5874540A (en) * 1994-10-05 1999-02-23 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
GB9621295D0 (en) 1995-12-07 1996-11-27 Cambridge Antibody Tech Specific binding members,materials and methods
US7232888B2 (en) 2002-07-01 2007-06-19 Massachusetts Institute Of Technology Antibodies against tumor surface antigens
KR20050065587A (ko) 2002-10-08 2005-06-29 이뮤노메딕스, 인코오포레이티드 항체 치료법
WO2005086875A2 (en) 2004-03-11 2005-09-22 City Of Hope A humanized anti-cea t84.66 antibody and uses thereof
NZ569204A (en) 2005-12-21 2012-03-30 Micromet Ag Pharmaceutical compositions with resistance to soluble CEA - comprising antibodies that bind to CD3 and CEA
US20070249014A1 (en) 2006-02-10 2007-10-25 Invitrogen Corporation Labeling and detection of post translationally modified proteins
WO2009102820A2 (en) 2008-02-11 2009-08-20 Government Of The U.S A., As Represented By The Secretary, Department Of Health And Human Services Modified sugar substrates and methods of use
CA2770174A1 (en) 2009-08-31 2011-03-03 Roche Glycart Ag Affinity-matured humanized anti cea monoclonal antibodies
ES2664989T3 (es) 2010-10-01 2018-04-24 National Research Council Of Canada Anticuerpos ANTI-CEACAM6 y usos de los mismos
KR101981342B1 (ko) 2011-03-02 2019-05-22 로슈 글리카트 아게 Cea 항체
HRP20180268T4 (hr) 2012-10-23 2026-03-27 Synaffix B.V. Modificirano antitijelo, konjugat antitijela i postupak za njihovu pripremu
PT3199552T (pt) 2012-11-20 2020-03-25 Sanofi Sa Anticorpos anti-ceacam5 e suas utilizações
US9567340B2 (en) * 2012-12-21 2017-02-14 Medimmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
EP3066470A4 (en) * 2013-11-05 2017-05-31 Immunomedics, Inc. Humanized anti-ceacam5 antibody and uses thereof
EP3177633B1 (en) 2014-08-04 2022-07-20 SynAffix B.V. Process for the modification of a glycoprotein using a beta-(1,4)-n-acetylgalactosaminyltransferase or a mutant thereof
EP3733209A1 (en) 2014-10-03 2020-11-04 Synaffix B.V. Sulfamide linker, conjugates thereof, and methods of preparation
JP6815329B2 (ja) 2015-03-23 2021-01-20 バイエル ファーマ アクチエンゲゼルシャフト 抗ceacam6抗体およびその使用
CN107810273B (zh) 2015-04-23 2022-09-27 西纳福克斯股份有限公司 用为或衍生自β-(1,4)-N-乙酰半乳糖胺转移酶的糖基转移酶修饰糖蛋白的方法
WO2017137456A1 (en) * 2016-02-08 2017-08-17 Synaffix B.V. Bioconjugates containing sulfamide linkers for use in treatment
WO2017137457A1 (en) * 2016-02-08 2017-08-17 Synaffix B.V. Antibody-conjugates with improved therapeutic index for targeting cd30 tumours and method for improving therapeutic index of antibody-conjugates
WO2017137458A1 (en) * 2016-02-08 2017-08-17 Synaffix B.V. Antibody-conjugates with improved therapeutic index for targeting cd30 tumours and method for improving therapeutic index of antibody-conjugates
CA3026651A1 (en) 2016-06-09 2017-12-14 Blinkbio, Inc. Silanol based therapeutic payloads
EP3720504A1 (en) 2017-12-06 2020-10-14 Synaffix B.V. Enediyne conjugates
TWI920652B (zh) 2018-06-07 2026-04-01 美商思進公司 喜樹鹼結合物
KR20240104214A (ko) 2019-03-29 2024-07-04 메디뮨 리미티드 화합물 및 이의 접합체
RS64961B1 (sr) 2019-04-26 2024-01-31 Immunogen Inc Derivati kamptotecina
AU2020350205A1 (en) 2019-09-18 2022-05-12 Lamkap Bio Alpha AG Bispecific antibodies against CEACAM5 and CD3
KR20230021018A (ko) 2020-06-05 2023-02-13 재단법인 생물기술개발중심 항-메조텔린 항체를 함유하는 항체-약물 컨쥬게이트 및 이의 용도
NL2026947B1 (en) 2020-11-20 2022-07-01 Synaffix Bv Tyrosine-based antibody conjugates
CN113816969B (zh) 2021-04-30 2024-01-16 联宁(苏州)生物制药有限公司 依喜替康类化合物、其抗体药物偶联物及其应用
US12533419B2 (en) 2021-07-19 2026-01-27 Mabplex International Co., Ltd. Antibody drug conjugate loaded with binary toxins and its application

Similar Documents

Publication Publication Date Title
JP2025510623A5 (cg-RX-API-DMAC10.html)
JP2023534131A5 (cg-RX-API-DMAC10.html)
EP0180564B1 (en) Immunogenic complex, a method for producing the same, and the use thereof as an immune stimulant, vaccines and reagents
US5391723A (en) Oligonucleotide conjugates
JP2020114818A5 (cg-RX-API-DMAC10.html)
Jennings et al. Induction of meningococcal group B polysaccharide-specific IgG antibodies in mice by using an N-propionylated B polysaccharide-tetanus toxoid conjugate vaccine.
JP5933923B2 (ja) 新規な複合タンパク質及びペプチド
Baldo et al. C-reactive protein-like precipitins in plaice
JP2024028453A5 (cg-RX-API-DMAC10.html)
US6800728B2 (en) Hydrazine-based and carbonyl-based bifunctional crosslinking reagents
JP2024010112A5 (cg-RX-API-DMAC10.html)
JP2002513028A (ja) ポリサッカリド抗原結合体
JP2021517113A5 (cg-RX-API-DMAC10.html)
JP2001506990A (ja) 一価の(monovalent)抗体フラグメント
IE58088B1 (en) Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
EP0206852A1 (fr) Conjugué constitué d'une adhésine de paroi de Streptococcus mutans, de nature protéique et d'un polysaccharide de Streptococcus mutans, sa préparation et son utilisation notamment dans des vaccins anti-caries
JP2012021161A (ja) シアニン色素
JP2006514627A5 (cg-RX-API-DMAC10.html)
JP2025060958A5 (cg-RX-API-DMAC10.html)
JPH01230592A (ja) T―抗原決定基を有する免疫吸着剤
JP2002504096A (ja) タンパク質−多糖ワクチンの調製のための未修飾タンパク質とハロアシルまたはジハロアシル誘導体化された多糖との結合
JP2005530493A5 (cg-RX-API-DMAC10.html)
JP2008518953A5 (cg-RX-API-DMAC10.html)
JP2025510700A5 (cg-RX-API-DMAC10.html)
JP2004529881A5 (cg-RX-API-DMAC10.html)